Project A3sc - An Atlas of Airways at a Single Cell Level

Respiratory System Clinical Trial

— AAAsc  

Official title:

Project A3sc - An Atlas of Airways at a Single Cell Level

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03437122
• Other study ID #: 17-PP-14
• Status: Completed
• Phase: N/A
• Start date: June 20, 2018
• Est. completion date: July 16, 2019

Study information

• Verified date: December 2019
• Source: Centre Hospitalier Universitaire de Nice
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The increasing incidence of chronic respiratory diseases is a public health problem affecting hundreds of thousands of people around the world, including children. Directly exposed to atmospheric aerocontaminants (pollution, allergens), the respiratory tracts represent a complex ecosystem that involves different cells that develop complex interactions with the surrounding connective tissue but also with their rich immune environment and with the microbiota. Although a pathophysiological continuum is postulated between the nasal and bronchial airways in certain diseases, such as allergic diseases, we have identified broad gradients in gene expression between nasal and bronchial samples. This is why cellular variability throughout the respiratory tree needs to be studied in detail.

The sequencing of RNAs specifically present in a particular cell, and its comparison with neighboring cells, allows us to document precise cellular contributions and intercellular relationships. Our project will establish protocols to stabilize airway swabs by brushing and/or biopsy, under conditions that will then allow the analysis of gene expression profiles at the single cell level (single cell RNA sequencing).

The development of the "single cell" stabilisation and analysis protocol will first be carried out on primary respiratory epithelium cultures and then extended to respiratory specimens taken from healthy volunteers. Through sampling at several levels of the respiratory tree, variations in expression along the tracheobronchial axis will be fully documented. Finally, the interaction between the epithelial compartment and the immunological compartment will be studied by analyzing gene expression on a single cell in different physiopathological contexts.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: July 16, 2019
• Est. primary completion date: July 16, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• age = 18 years and <40 years

• non-smoker

• absence of known acute or chronic disease

• absence of symptoms suggestive of progressive disease

• normal clinical examination

Exclusion Criteria:

• recent rhino-bronchial infection (<6 weeks)

• mental disability

• pregnant women (a urine test will be performed for all women of childbearing age)

Related Conditions & MeSH terms

• Respiratory System

Intervention

Procedure:
• Bronchoscopy
Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)

Locations

Country	Name	City	State
France	CHU de Nice	Nice

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nice

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of samples usable		6 months